This document summarizes the credentials and experience of Dun Li, Ph.D., a cancer biologist and research scientist. Li has over 10 years of experience in molecular biology, cancer research, and drug development. He is currently a postdoctoral fellow at Boston University developing transgenic zebrafish models of breast cancer, leukemia, and neuroblastoma. Previously, Li received his Ph.D. from Stony Brook University studying mutant p53 and cancer drug resistance. He has authored 7 peer-reviewed publications and received NIH training grants. Li is seeking a position where he can apply his expertise in cancer biology, molecular biology techniques, and animal model development.
A normal cell can be transformed into a cancerous cell. Discuss the therapeutic strategies that are employed to target the cellular transformation process for cancer prevention and treatment.
The use of genetic engineering technology in animals has been associated with ethical issues, some of which relate to animal welfare. Discuss examples of genetically engineering animals and evaluate the ethical concerns of genetic engineering.
Professor Joe Trapani, Executive Director Cancer Research,
Peter MacCallum Cancer Centre, Melbourne. http://www.garvan.org.au/news-events/leaders-in-science-and-society
A normal cell can be transformed into a cancerous cell. Discuss the therapeutic strategies that are employed to target the cellular transformation process for cancer prevention and treatment.
The use of genetic engineering technology in animals has been associated with ethical issues, some of which relate to animal welfare. Discuss examples of genetically engineering animals and evaluate the ethical concerns of genetic engineering.
Professor Joe Trapani, Executive Director Cancer Research,
Peter MacCallum Cancer Centre, Melbourne. http://www.garvan.org.au/news-events/leaders-in-science-and-society
A normal cell can be transformed into a cancerous cell. Discuss the therapeutic strategies that are employed to target the cellular transformation process for cancer prevention and treatment.
This presentation contain information about molecular biology and laboratory technics, specially alternative splicing.
all of them to try to explain cancer etiology, give on the molecular bases.
The culture of cells in two dimensions does not reproduce the histological characteristics of a tissue for informative or useful study. Growing cells as three-dimensional (3D) models more analogous to their existence in vivo may be more clinically relevant. Discuss the potential of using three dimensional cell cultures for anti-cancer drug screening.
Genes and Tissue Culture Assignment Presentation (Group 3)Lim Ke Wen
The culture of cells in two dimensions does not reproduce the histological characteristics of a tissue for informative or useful study. Growing cells as three-dimensional (3D) models more analogous to their existence in vivo may be more clinically relevant. Discuss the potential of using three dimensional cell cultures for anti-cancer drug screening.
Dr. Talita Resende - Organoids as an invitro model for enteric diseasesJohn Blue
Organoids as an invitro model for enteric diseases - Dr. Talita Resende, from the 2018 Allen D. Leman Swine Conference, September 15-18, 2018, St. Paul, Minnesota, USA.
More presentations at http://www.swinecast.com/2018-leman-swine-conference-material
Prof Richard Gibbs - Director, Baylor College of Medicine Human Genome Sequencing Centre
Wofford Cain Professor of Human & Molecular Genetics. http://www.garvan.org.au/news-events/leaders-in-science-and-society
Dr. David Guillespie - Identificación de dianas de daño en el DNA en la terap...CIBICAN - ULL
Presentación del Dr. David Guillespie, investigador contratado por el CIBICAN - Universidad de La Laguna gracias al Proyecto Europeo IMBRAIN, en relación a los resultados alcanzados durante la ejecución del mismo y los planes de futuro. La misma se presentó durante las Jornadas IMBRAIN llevadas a cabo el 13 de Octubre de 2015 en la Sección de Física en la Universidad de La Laguna
Genes and Tissue Culture Technology Assignment (G6)Rohini Krishnan
The culture of cells in two dimensions does not reproduce the histological characteristics of a tissue for informative or useful study. Growing cells as three-dimensional (3D) models more analogous to their existence in vivo may be more clinically relevant.
A normal cell can be transformed into a cancerous cell. Discuss the therapeutic strategies that are employed to target the cellular transformation process for cancer prevention and treatment.
This presentation contain information about molecular biology and laboratory technics, specially alternative splicing.
all of them to try to explain cancer etiology, give on the molecular bases.
The culture of cells in two dimensions does not reproduce the histological characteristics of a tissue for informative or useful study. Growing cells as three-dimensional (3D) models more analogous to their existence in vivo may be more clinically relevant. Discuss the potential of using three dimensional cell cultures for anti-cancer drug screening.
Genes and Tissue Culture Assignment Presentation (Group 3)Lim Ke Wen
The culture of cells in two dimensions does not reproduce the histological characteristics of a tissue for informative or useful study. Growing cells as three-dimensional (3D) models more analogous to their existence in vivo may be more clinically relevant. Discuss the potential of using three dimensional cell cultures for anti-cancer drug screening.
Dr. Talita Resende - Organoids as an invitro model for enteric diseasesJohn Blue
Organoids as an invitro model for enteric diseases - Dr. Talita Resende, from the 2018 Allen D. Leman Swine Conference, September 15-18, 2018, St. Paul, Minnesota, USA.
More presentations at http://www.swinecast.com/2018-leman-swine-conference-material
Prof Richard Gibbs - Director, Baylor College of Medicine Human Genome Sequencing Centre
Wofford Cain Professor of Human & Molecular Genetics. http://www.garvan.org.au/news-events/leaders-in-science-and-society
Dr. David Guillespie - Identificación de dianas de daño en el DNA en la terap...CIBICAN - ULL
Presentación del Dr. David Guillespie, investigador contratado por el CIBICAN - Universidad de La Laguna gracias al Proyecto Europeo IMBRAIN, en relación a los resultados alcanzados durante la ejecución del mismo y los planes de futuro. La misma se presentó durante las Jornadas IMBRAIN llevadas a cabo el 13 de Octubre de 2015 en la Sección de Física en la Universidad de La Laguna
Genes and Tissue Culture Technology Assignment (G6)Rohini Krishnan
The culture of cells in two dimensions does not reproduce the histological characteristics of a tissue for informative or useful study. Growing cells as three-dimensional (3D) models more analogous to their existence in vivo may be more clinically relevant.
Advances in Childhood Cancer: Big Data & Immunotherapeutics
Friday, 31st August, 2018
Venue: Australian National Maritime Museum, Darling Harbour, Sydney
KCA warmly invites you to this symposium featuring the latest developments in big data analytics, bioinformatics and, immunotherapeutic targeting.
Registration is FREE.
Seating is limited*. To register please email your full name, preferred email address, and name of your primary institution to KCAadmin@ccia.org.au
For more details please contact Dr Michael Evtushenko MEvtushenko@ccia.unsw.edu.au
iOncologi_Pitch Deck_2024 slide show for hostinger
Li Resume
1. Dun Li, Ph.D.
Cancer Biologist
Research and Development Scientist
Highly motivated, trained and skilled Ph.D. scientist with a solid record of achievements and publications
looking for a position to utilize my scientific experience and expertise to make significant contributions in
fighting human cancer and other diseases.
Key Personal Skills
Fast Learner
Excellent communication skills
Team Leadership
High level of computer expertise
Extensive teaching experience
Bilingual (English and Mandarin)
Key Technical Skills
Molecular biology (DNA, RNA, protein purification and analysis, etc)
Cellular biology (culture, cryopreservation, transfection, infection, etc)
Targeting vector designing both in vivo and in vitro
Large scale live animal handling (mice and zebrafish)
Large scale drug screening both in vitro and in vivo
Crispr/Cas9 targeted genome editing
Cellular and biochemical assay development
Grant and manuscript writing and editing
Areas of Expertise
Cancer biology
Oncology
Cancer metabolomics
Molecular and cellular biology
Assay development
Professional Experience
Boston University, Boston, MA 9/14 – present
Postdoctoral Fellow
In Dr. Hui Feng’s lab, I am responsible for pioneering and leading multiple projects and personnel. Currently I
am focused on a breast cancer metabolism project, developing two new transgenic zebrafish leukemia models,
and a new transgenic zebrafish neuroblastoma model. My duties include: studying relevant literature,
designing experiments, analyzing results, troubleshooting and the training and organization of lab personnel.
Stony Brook University, Stony Brook, NY 9/08 – 8/14
Graduate Student under the mentorship of Dr. Ute Moll
Screened and developed novel treatments for human breast cancer using two or more inhibitors
Characterized the mechanism of chemotherapeutic drug resistance in human breast cancer cell lines
Discovered a novel mutant p53 function that drives tumor development
2. Evaluate drug treatments in vivo using mutant p53 knock in mice
Training and leading lab technicians and graduate students
GeneHarbor (Hong Kong) Biotechnologies Limited, Hong Kong, China 7/05 – 8/08
Part Time Research Assistant
Created and purified multiple heat resistant enzymes to biosynthesize the antidepressant SAMe
Helped design and evaluate assays to synthesize and purify SAMe
Education
The Chinese Universityof Hong Kong, Hong Kong, China 9/04-5/08
Bachelor of Science
Academic and Professional Honors
NIH T32 Pre-doc Cancer training grant 2012-2014
NIH T32 Post-doc Cancer training grant 2014-2016
Memberships in Professional Societies
AAAS member
Zebrafish Disease Model Society member
Research papers
1. ND Marchenko, W Hanel, D Li, K Becker, N Reich, UM Moll. 2010. Stress-mediated nuclear
stabilization of p53 is regulated by ubiquitination and importin-α3 binding. Cell Death & Differentiation
17 (2), 255-267
2. Dun Li, Natalia D Marchenko, Ramona Schulz, Victoria Fischer, Talia Velasco-Hernandez, Flaminia
Talos, Ute M Moll. 2011. Functional inactivation of endogenous MDM2 and CHIP by HSP90 causes
aberrant stabilization of mutant p53 in human cancer cells. Molecular Cancer Research 9 (5), 577-588
3. D Li, ND Marchenko, UM Moll. 2011. SAHA shows preferential cytotoxicity in mutant p53 cancer cells
by destabilizing mutant p53 through inhibition of the HDAC6-Hsp90 chaperone axis. Cell Death &
Differentiation 18 (12), 1904-1913
4. D Li, A Yallowitz, L Ozog, N Marchenko. 2014. A gain-of-function mutant p53–HSF1 feed forward
circuit governs adaptation of cancer cells to proteotoxic stress. Cell death & disease 5 (4), e1194
5. AR Yallowitz, D Li (co-first author), A Lobko, D Mott, A Nemajerova, N Marchenko. 2015. Mutant p53
amplifies Epidermal Growth Factor Receptor family signaling to promote mammary tumorigenesis.
Molecular Cancer Research. 0360.2014
6. EM Alexandrova, AR Yallowitz, D Li, S Xu, R Schulz, DA Proia, G Lozano, M Dobbelstein, UM Moll.
2015. Improving survival by exploiting tumour dependence on stabilized mutant p53 for treatment.
Nature, 523, 352–356
7. Anderson NM, Li D, Peng HL, Laroche FJ, Mansour MR, Gjini E, Aioub M, Helman DJ, Roderick JE,
Cheng T, Harrold I, Samaha Y, Meng L, Amsterdam A, Neuberg DS, Denton TT, Sanda T, Kelliher MA,
Singh A, Look AT, Feng H. 2015 The TCA cycle transferase DLST is important for MYC-mediated
leukemogenesis. Lekemia, Feb 15 (epub ahead of print)